​Kite: A High-Flier in Oncology

MoneyShow  |

Monster winners often have one trait in common: triple-digit revenue growth. Kite Pharmaceuticals (KITE) could soon reach this milestone, notes growth stock expert Mike Cintolo, editor of Cabot Top Ten Trader.

Revenue was up 92% in Q1, and should be up 90% this year, then soar over 350% next year! In addition, the stock ticks a few other boxes in the potential big winner column, too.

It is progressing from a clinical-stage biotech stock to a commercial-stage company with life-saving treatments in the emerging field of cancer immunotherapy.

It doesn’t have a drug on the market just yet (Q1 revenue was from collaborations and license agreements with Amgen (AMGN) and Daiichi Sankyo.

But data show Kite’s most advanced candidate axi-cel; KTE-C19 is a potential game-changing treatment for a range of blood cancers.

It is a CAR-T cell therapy, meaning Kite takes a patient’s own white blood cells and genetically engineers them to recognize and destroy the cancer.

Kite submitted a marketing application to the FDA earlier this year, plans to submit one to the EU in Q3, and expects to hear from the FDA in November. The company is prepping for a commercial rollout in the U.S. now, with a global rollout to follow.

Suffice it to say, investors have a lot riding on the FDA’s PDUFA date on November 29. And based on recent price target increases, analysts see the probability of success going up.

Mike Cintolo is Vice President of Investments and Chief Analyst at Cabot Heritage Corporation.

Subscribe to Mike Cintolo’s Cabot Top Ten Trader here…

About MoneyShow.com: Founded in 1981, MoneyShow is a privately held financial media company headquartered in Sarasota, Florida. As a global network of investing and trading education, MoneyShow presents an extensive agenda of live and online events that attract over 75,000 investors, traders and financial advisors around the world.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Companies

Symbol Name Price Change % Volume
AMGN Amgen Inc. 237.60 -3.89 -1.61 3,094,208 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019